Trailblazing Therapy: IBR900 Cellular Injection Enters Phase I Trial

On July 1, 2025, the initiation meeting for the Phase I clinical trial of IBR900 cellular injection—developed by ImmuneCell BioRay (Hangzhou) Co., Ltd.—for treating B-cell non-Hodgkin lymphoma was successfully held at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.

🤝 Leadership & Collaboration

• Co-Leads:
  • Professor Zhao Weili (Ruijin Hospital, Shanghai Jiao Tong University)
  • Professor Tong Hongyan (First Affiliated Hospital, Zhejiang University School of Medicine)
• Collaborating Centers: Top clinical research institutions, including Sun Yat-sen University Cancer Center.

🧑‍⚕️ Key Participants & Agenda

• Attendees:
  • Professor Zhao Weili’s hematology clinical research team (Ruijin Hospital)
  • Dr. Mei Shuang, CTO of ImmuneCell BioRay
  • ImmuneCell BioRay clinical team
  • Operations team from CRO Yaocheng Bio
• Host: Dr. Sheng Lingshuang (Ruijin Hospital)
• Focus: Detailed review of the Phase I protocol’s implementation process
• Discussion: Participants extensively analyzed major trial challenges, offering actionable solutions and recommendations to ensure smooth execution.

🚀 Trial Commencement & Next Steps

The successful meeting officially marks the launch of the Phase I clinical trial and the beginning of participant recruitment.

ImmuneCell BioRay will collaborate with clinical centers and experts to progress the study with high quality and efficiency, aiming for impactful outcomes that benefit patients suffering from B‑cell non‑Hodgkin lymphoma.

🧬 What Is IBR900 Cellular Injection?

• Product Type: Off-the-shelf, allogeneic NK cells derived from healthy young donors’ PBMCs.
• Genetic Profile: Non-genetically modified; potent tumor-cell killing capability.
• Manufacturing: Produced via ImmuneCell BioRay’s proprietary culture technology, activating NK cells without prior sensitization.
• Safety Profile: Demonstrated high safety—no observed CRS, ICANS, or GVHD.
• Mechanism of Action:
  1. Direct NK-cell–mediated cytotoxicity
  2. Cytokine secretion
  3. Apoptosis induction
  4. ADCC enhancement when paired with monoclonal antibodies targeting tumor antigens
• Clinical Evidence: Investigator-initiated trials (IITs) have shown excellent safety and promising efficacy, offering new therapeutic potential and hope for B‑cell non‑Hodgkin lymphoma patients.

About DengYueMed—HK Drug Wholesale Distributor

As a legally compliant drug import and export company, DengYue is certified by the Pharmacy & Poisons Board of Hong Kong — you can verify our qualification on their official website.

Our efforts to improve the affordability of  IBR900 Cellular Injection aim to ensure that more patients can benefit from this important medication.

HK DengYue provides detailed medicine information, transparent pricing, and responsive support to ensure a smooth and reliable buying experience.

Feel free to reach out anytime to discuss your needs or ask questions about the medicine. We welcome you to contact us for a consultation.